News | Sudden Cardiac Arrest | May 13, 2022

MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

The Neurescue device is an FDA-approved device for use in patients with severe bleeding to help increase survival rate for those who experience in-hospital cardiac arrests

The Neurescue device is an FDA-approved device for use in patients with severe bleeding to help increase survival rate for those who experience in-hospital cardiac arrests

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only national site to offer and enroll patients in the ARISE-Study to help increase survival rates for those who experience in-hospital cardiac arrests. The study uses the Neurescue device – a catheter-based balloon that is inserted through the groin into the aorta – to help improve circulation and blood pressure, while standard treatment happens in parallel. When the balloon inflates, it helps keep blood in the upper part of the body to circulate to the heart and the brain. This improved circulation and blood pressure can improve efforts to restart the heart.

"Seventy-five percent of patients with cardiac arrest die because they don't respond to current standard treatments of cardiopulmonary resuscitation (CPR), defibrillation and medicine," says David Shavelle, M.D., medical director, adult cardiology and interventional lab, MemorialCare Heart & Vascular Institute, Long Beach Medical Center. "This device gives us an extended chance at saving a life."

The ARISE-study is designed to see if this device can help a patient in cardiac arrest who has already received eight minutes of standard treatment but has not responded to it. Only physicians who've been trained in implanting this device will be allowed to use it during a cardiac arrest code. The patient may be enrolled in the study at that time. Since the risk of death after eight minutes of unsuccessful cardiac arrest treatment is very high, the investigators of the study believe the benefit of the device will outweigh any risk of device placement.

"The potential results of this study and device could fundamentally change how we treat and manage cardiac arrests in the hospital setting," said Shavelle. "If we are able to augment our standard treatment protocols to give cardiac arrest patients a greater chance of restarting their heart, this could really be a game changer and an advance desperately needed in the medical community."

If the medical team is able to restart the patient's heart with the device, the device would be left in place and the balloon deflated. The tube and balloon will be removed within an hour and the patient will be closely monitored in the cardiac intensive care unit.

The device is currently approved by the Food and Drug Administration (FDA) for use in patients with severe bleeding and is being used. throughout the U.S. for this indication.

For more information: memorialcare.org/LongBeach

Related Content

News | Heart Failure

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and ...

Home May 16, 2022
Home
News | Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
News | Heart Failure

May 5, 2022 – Cardiovascular disease is a group of conditions that can arise from a lack of physical activity, poor diet ...

Home May 05, 2022
Home
Feature | Heart Failure | By Jean-Luc Boulnois, Ph.D.

The current standard of care for heart failure (HF) is guideline-directed medical therapy combined with device-based ...

Home May 04, 2022
Home
News | Heart Failure
April 27, 2022 – The contractile and elastic properties of the heart are finely tuned. This is a prerequisite for the ...
Home April 27, 2022
Home
News | Heart Failure

April 25, 2022 — Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer ...

Home April 25, 2022
Home
News | Heart Failure

April 20, 2022 – The Pulmonary Hypertension Association (PHA) joins more than 80 organizations around the world on ...

Home April 20, 2022
Home
News | Heart Failure

April 19, 2022 – What happens below the cellular level when the heart contracts and relaxes has long been unexplored ...

Home April 19, 2022
Home
News | Heart Failure
April 19, 2022 – New breakthrough research by a University of South Florida lab team describing how certain fats can ...
Home April 19, 2022
Home
News | Heart Failure
April 19, 2022 – It is estimated that about one in four adults worldwide has a liver condition that is a risk factor for ...
Home April 19, 2022
Home
Subscribe Now